TELA Bio

129 articles about TELA Bio

• TELA Bio to Participate in Piper Sandler’s 35th Annual Healthcare Conference

  11/16/2023

  TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will participate in Piper Sandler’s 35th Annual Healthcare Conference.

• TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 10, 2023

  11/10/2023

  TELA Bio, Inc. announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 40,700 shares of its common stock to thirty-one newly-hired employees, with a grant date of November 6, 2023.

• TELA Bio Reports Third Quarter 2023 Financial Results

  11/9/2023

  TELA Bio, Inc. reported financial results for the third quarter ended September 30, 2023.

• TELA Bio to Announce Third Quarter 2023 Financial Results

  10/26/2023

  TELA Bio, Inc. announced that the Company will report third quarter 2023 financial results on Thursday, November 9, 2023.

• TELA Bio to Participate in the Gilmartin Group Emerging Growth Company Showcase

  9/18/2023

  TELA Bio, Inc. (NASDAQ: TELA) today announced that the Company will participate in the Gilmartin Group Emerging Growth Company Showcase.

• TELA Bio Reports Second Quarter 2023 Financial Results

  8/9/2023

  TELA Bio, Inc. reported financial results for the second quarter ended June 30, 2023.

• TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 04, 2023

  8/4/2023

  TELA Bio, Inc. announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 26,250 shares of its common stock to twenty-two newly-hired employees, with a grant date of August 1, 2023.

• TELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference

  7/26/2023

  TELA Bio, Inc. today announced that the Company will report second quarter 2023 financial results on Wednesday, August 9, 2023.

• TELA Bio Invests in Surgeon Training and Education with Upcoming Cadaver LabCompany prioritizes education with a variety of in-person and virtual training programs

  5/19/2023

  TELA Bio, Inc today announced it will be hosting its next cadaver lab on May 19 in Tampa, Florida.

• TELA Bio Reports First Quarter 2023 Financial Results

  5/11/2023

  TELA Bio, Inc. reported financial results for the first quarter ended March 31, 2023.

• TELA Bio Supports Diversity and Inclusion at International Hernia Collaboration ConferenceLeader in innovative soft-tissue tissue reconstruction solutions sponsors event advocating for and mentoring women in surgery

  5/9/2023

  TELA Bio, Inc., a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, will sponsor a Women in Surgery Dinner on May 10, 2023, at the International Hernia Collaboration Conference in Rio de Janeiro, Brazil.

• TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 08, 2023

  5/8/2023

  TELA Bio, Inc. announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 27,250 shares of its common stock to seventeen newly-hired employees, with a grant date of May 5, 2023.

• TELA Bio to Announce First Quarter 2023 Financial Results

  4/27/2023

  TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA) today announced that the company will report first quarter 2023 financial results on Thursday, May 11, 2023.

• TELA Bio Announces Pricing of Public Offering of Common Stock - April 19, 2023

  4/19/2023

  TELA Bio, Inc. announced the pricing of its previously announced underwritten public offering of 4,750,000 shares of its common stock at a price to the public of $9.50 per share, for gross proceeds of $45.125 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

• TELA Bio Announces Proposed Public Offering of Common Stock - April 18, 2023

  4/18/2023

  TELA Bio, Inc. announced that it has commenced an underwritten public offering of shares of its common stock.

• TELA Bio’s OviTex® Reinforced Tissue Matrix to be Featured in Three Case Reports at SAGES 2023

  3/29/2023

  TELA Bio, Inc today announced its OviTex ® Reinforced Tissue Matrix will be featured in three case reports at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) conference from March 29 - April 1, 2023, in Montreal, Canada.

• TELA Bio Announces 510(k) Clearance for OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

  3/23/2023

  TELA Bio, Inc today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Company's OviTex PRS Long-Term Resorbable product.

• TELA Bio Reports Fourth Quarter and Full Year 2022 Financial Results

  3/21/2023

  TELA Bio, Inc. ("TELA Bio") today reported financial results for the fourth quarter and full year ended December 31, 2022.

• TELA Bio Highlights Published Clinical Research from 2022 Showcasing Safety and Performance of Reinforced Biologic for Hernia Indications

  3/16/2023

  TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today highlights six studies published in 2022.

• TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 24, 2023

  2/24/2023

  TELA Bio, Inc. announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 2,600 shares of its common stock to three newly-hired employees, with a grant date of February 21, 2023.